Regeneron Pharmaceut

REGN
Delayed Nasdaq - 07/19 10:00:00 pm
298.11USD
-1.64%
Prev.303.0900
Open303.5200
High303.6831
Low296.3500
Volume548 042
Financials
Sales 2019 7 351 M
EBIT 2019 2 153 M
Net income 2019 1 948 M
Finance 2019 5 399 M
Yield 2019 -
P/E ratio 2019 18,0x
P/E ratio 2020 14,8x
EV / Sales2019 3,69x
EV / Sales2020 3,19x
Capitalization 32 544 M
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows:
- sales of products (61.2%);
- supply of collaborative services (32.6%): working with Sanofi...
Sector :
Bio Therapeutic Drugs
Calendar :
2019-08-06 Earnings Release
Trading Rating :
Investor Rating :
Latest news
07/19REGENERON PHARMACEUTICALS : Statement Regarding Praluent® (alirocumab) in Germany
PU
07/18REGENERON PHARMACEUTICALS : Announces the 2019 Winners of the Prize for Creative Innovation
PR
07/11REGENERON PHARMACEUTICALS : Statement Regarding Düsseldorf Regional Court Decision in Ongoing Praluent® (alirocumab) Patent Litigation in Germany
PU
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/08REGENERON PHARMACEUTICALS : to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019
PR
07/02SANOFI : - Libtayo approved for advanced cutaneous squamous cell carcinoma in the European Union
AQ
07/02REGENERON PHARMACEUTICALS : Libtayo Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishBearish
Resistance305344357
Spread/Res.-2,3%-13%-16%
Spread/Supp.2,2%2,2%1,9%
Support292292293